Summary: Jennifer Baldock, Chief Admin & Dev Officer at Surgery Partners, Inc. (NASDAQ:SGRY), executed a sale of 10,082 common shares on March 6, 2026, at $13.70 per share, producing proceeds of $138,123. The transaction followed a restricted stock award on March 5, 2026, in which Baldock received 106,207 shares at a reported price of $14.11 each, with a total reported value of $1,499,991. The stock disposition was carried out to satisfy tax liabilities arising from the vesting of those restricted shares. After these moves, Baldock is recorded as directly owning 332,272 shares of Surgery Partners.
The Form 4 filing with the Securities and Exchange Commission recorded both the sale and the restricted stock grant. The sale amount and the reason provided - covering tax obligations related to the restricted stock vesting - are itemized in the filing. The earlier restricted award is reflected at the $14.11 price and the aggregate value reported by the filing.
Outside of insider activity, Surgery Partners has been the subject of recent operational and financial developments that have influenced investor and analyst perspectives. The company reported adjusted EBITDA-NCI results that fell 6% below consensus estimates, a gap that TD Cowen attributed to a negative insurance mix shift and operational issues at three surgical hospitals. In response to the weaker-than-expected earnings and softer guidance for 2026, several analysts adjusted their price targets and maintained various ratings.
RBC Capital reduced its price target from $31 to $20 while retaining an Outperform rating, citing the softer guidance. Jefferies lowered its target from $28 to $16.25 but kept a Buy rating, referencing an earnings reset and what it described as a leveraged balance sheet. Benchmark also trimmed its target from $30 to $24, explicitly linking the move to weak fourth-quarter results and fiscal 2026 guidance that missed expectations.
On the strategic front, Surgery Partners completed an acquisition of Preferred Vascular Group, described in filings as a provider specializing in dialysis access procedures. The purchase - reported with a $6 billion market reference - brings eight ambulatory surgical centers in Georgia and Ohio into Surgery Partners' portfolio.
Separately, InvestingPro analysis noted that the stock appears undervalued at current levels and highlighted that subscribers can access additional ProTips and expanded financial metrics through its Pro Research Report. The combination of insider activity, recent operating results, adjusted guidance and notable acquisition activity frames the current investor landscape for Surgery Partners.
Note: All transaction amounts, dates and analyst actions above are taken from company filings and reported analyst commentary as stated in those items.